Retinoids, vitamin A and its natural and synthetic analogues have various functions, including being involved in cell proliferation and differentiation and participating in the formation of vertebrate morphology. In addition, they may activate certain tumour suppressor genes that then act as tumour inhibitors. In the past decades, retinoids have been regarded as promising chemotherapeutic and chemopreventive agents; however, their mechanisms are still not fully understood. Immune cells that participate in or are associated with the immune response play vital roles in the initiation and development of many cancers. Interestingly, recent studies have demonstrated that retinoids can also exert various effects on immune cells including macrophages, T cells and dendritic cells in tumour tissues to execute anti-tumour actions, providing new insights into chemoprevention and chemotherapeutics. In this review, we focus on the effects of retinoids on immune cells in the tumour, which may provide new approaches for antineoplastic strategies.
Introduction
Vitamin A is essential for normal growth in the body, it cannot be synthesized, and it is absorbed through the diet in the form of retinol, retinene, retinyl ester or β-carotene (Bushue and Wan, 2010) . Retinoids, vitamin A and its natural and synthetic analogues, are lipophilic isoprenoids that are composed of a highly conjugated terpene chain and a terminal polar group, including retinol, retinal, retinyl esters, retinoic acid (RA) and a variety of derivatives with these structures (Alizadeh et al., 2014) . Retinoids have many biological functions; for example, they can act as antioxidants, increase the activity of NK cells, and regulate cell proliferation and differentiation (Shen et al., 2009; Alizadeh et al., 2014) .
In recent years, the anti-tumour activity of retinoids has also received extensive attention. To date, many studies have indicated that retinoids can inhibit the growth of certain types of tumour cell lines (Bathaie et al., 2007) . In addition, many retinoids have potential for clinical use, and some have been used for several years. β-Carotene, a type of provitamin A carotenoid, has been studied for its ability to prevent lung cancers (Bushue and Wan, 2010) . Clinical trials have suggested that 13-cisRA can reduce the death rate from secondary aerodigestive tract tumours and is beneficial to patients with high-risk neuroblastoma after bone marrow transplantation (Bushue and Wan, 2010) . TAC-101, a synthetic retinoid, has the potential to suppress tumour growth in the liver, and it significantly decreases mortality from primary hepatocellular carcinoma, as well as metastatic colon cancer (Bushue and Wan, 2010) . The best-known therapeutic effect is the role that all-trans retinoic acid (ATRA) plays in the treatment of acute promyeloid leukaemia (APL) (Chen et al., 2014; Yin et al., 2015) (Table 1, Figure 1 ). Conventional wisdom holds that the classical mechanism of retinoid is activation of the transcription of specific target genes mediated by nuclear hormone receptors (Uray et al., 2016) . However, scientists have not yet reached full agreement on the antitumour mechanism of retinoids.
The effects of the tumour micro-environment on antitumour therapy have received widespread attention in the past few years. The tumour micro-environment is the cellular environment that is composed of various cell types and extracellular matrix components (Figure 2 ). Interactions between neoplastic cells and other substances, such as immune cells, fibroblasts, cytokines, other stroma cells and extracellular matrix proteins, frequently make a difference to the development of tumours (Song et al., 2014; Domingues et al., 2016) . It has been well demonstrated that immune cells including macrophages, T lymphocytes, dendritic cells (DCs), polymorphonuclear leukocytes and B lymphocytes serve dual functions -suppressing and promoting tumour growth (Domingues et al., 2016) . It is widely believed that some of these immune cells, such as helper T cells (Th cells), cytotoxic T cells (Tc cells), NK cells and mature DCs, are helpful towards fighting tumours in which regulatory T cells (Treg cells) have a complex functionality, and that macrophages and neutrophils can function as either tumour promoters or inhibitors (Hegmans and Aerts, 2014) . Infiltration by immune cells is an important hallmark of tumours and is usually involved in tumour progression and patient prognosis (Fridman et al., 2012; Quail and Joyce, 2013) . Nevertheless, the relationship between the presence of inflammatory infiltrates and the patient outcome is hard to judge, because there are great discrepancies as regards the different types and functional states of immune cells. Moreover, immune cells may have anti-or pro-tumoural effects depending on the different (Ponthan et al., 2001) tumour micro-environments and, therefore, may play dual roles in either suppressing or promoting malignancy . Research is well underway on treatments for cancer that are related to immune cells, such as the therapeutic DC vaccine, immune checkpoint inhibitors and therapy mediated by NK cells (Fleissner et al., 2011; Kochenderfer et al., 2012; Hamid et al., 2013; Anguille et al., 2014; Schadendorf et al., 2015; Zhu et al., 2016) . It is noteworthy that an increasing number of studies have found that many types of retinoids exhibit anti-tumour effects via regulation of diverse immune cells through complex and different mechanisms. Given the relationship between retinoids and immunity, we describe the prominent regulatory effects on immune cells that retinoids perform in the tumour.
Retinoids play a crucial role in regulating the differentiation, recruitment and polarization of macrophages
As an important component of innate and adaptive immunity, macrophages perform a vital role in clearing pathogens and
Figure 1
The structures of retinoids that are used in clinical and preclinical research. ATRA is widely used in the treatment of APL. Clinical trials suggested that 13-cisRA could reduce the death of second aerodigestive tract tumours. β-Carotene has been studied for the prevention of lung cancers. 9-cisRA has the potential to prevent mammary and prostate cancer. TAC-101 shows promise as a suppressor of tumour growth in the liver and decreases mortality in animal models of primary hepatocellular carcinoma and metastatic colon cancer. 4-HPR is expected to be used to treat ovarian and colon cancer.
Figure 2
The components of the tumour micro-environment. The tumour micro-environment is the cellular environment composed of the overall composition of various cell types and extracellular matrix components. Interactions between neoplastic cells and other substances like immune cells, fibroblasts, cytokines, other stroma cells and extracellular matrix proteins frequently make a difference in the development of tumours. Immune cells include macrophages, T lymphocytes, DCs, polymorphonuclear leukocytes and B lymphocytes cells. The blood vessel is a must for tumour growth.
maintaining tissue homeostasis. On the one hand, macrophages kill pathogens and clear foreign bodies, wounded tissues and cell debris through phagocytosis. On the other hand, they dispose of and present antigens and initiate and modulate immune responses to further reactions in the defence system (Mosser and Edwards, 2008) . Apart from their immune-modulating function, macrophages also play an essential part in the repair of damaged tissues and numerous pathological and physiological processes, especially in the occurrence and development of cancer. There is increasing evidence that malignancy is influenced by macrophages (Rhee, 2016) . As research continues, the effect that retinoids have on the macrophages to prevent and counter cancers has received widespread attention. Retinoids have been found to be a critical factor in the anti-tumour process, as they regulate the differentiation, recruitment and polarization of macrophages.
Retinoids promote the differentiation of macrophages
Macrophages are crucial immune effector cells with highly heterogeneous characteristics and are differentiated from monocytes that migrate from the blood to the liver, spleen, lymph node and other tissues and organs (Song et al., 2014) . Since macrophages are of great importance to the initiation and development of cancer, a compound that affects the differentiation of macrophages from monocytes directly influences tumour progression. ATRA has been used as a treatment for several types of cancers, especially in the therapy for APL. ATRA is the major active metabolic intermediate of vitamin A in animals, and it has extensive physiological and pharmacological activities. It is best known for its role in regulating gene expression in cell differentiation (Fields et al., 2007) . The transcriptional activity of the target genes can be markedly changed when ATRA binds to nuclear retinoic acid receptors (RARs), and activates downstream biological effects (Bastien and Rochette-Egly, 2004) . Various studies that have been conducted in human THP-1 cells, a widely used model for monocytic differentiation, have shown that cell cycle progression is affected by ATRA with enhanced phagocytic activity, as well as increased expression of CD11b, a typical cell surface hallmark of macrophage differentiation (Tsuchiya et al., 1980; Kronenberg, 2003; Chen and Ross, 2004; Maves and Kimmel, 2005) . Zhang et al. (2012) investigated the effect of ATRA on the transcription factor MafB, which induces the differentiation of monocytes to macrophages. MafB is a well-known transcription factor that regulates early embryonic development (Hernandez et al., 2004; Maves and Kimmel, 2005) . It is also considered an important regulator of macrophage differentiation because it has been found to be expressed in monocytes and macrophages (Kelly et al., 2000; Bakri et al., 2005) . In the study of Zhang et al. (2012) , both the levels of MafB mRNA and protein were dose-and time-dependently up-regulated by ATRA in THP-1 cells, and both phagocytic activity and the expression of CD11b were enhanced (Zhang et al., 2012) . The mechanism by which ATRA modulates the MafB gene remains to be elucidated, while studies have strongly indicated that MafB regulates cell behaviour by targeting genes such as SPOCK1, Blimp1 and CCL2 (Zhang et al., 2012) . The activation of NF-κB has also been shown to be an essential event in macrophage differentiation both in vivo and in vitro; it determines the lineage-specific differentiation of myeloid leukaemia cells induced by ATRA (Imran et al., 2015) . The data from this latter study revealed that the nuclear translocation of NF-κB was increased by ATRA treatment in HL-60 cells, a leukaemia cell line. The ability of ATRA to induce differentiation to macrophages is enhanced, while differentiation to granulocytes is decreased by activated NF-κB, with morphological changes and increased expression of differentiation markers such as CD11b, CD38 and CD68 (Imran et al., 2015) . Furthermore, MAPK was observed to be pivotal in the process of NF-κB activation regulated by ROS (Imran et al., 2015) . The advantage of stimulating myeloid leukaemia cells differentiation to macrophages may be the enhancement of sensitivity and overcoming of resistance to ATRA treatment (Witcher et al., 2004) .
Retinoids inhibit the recruitment and activation of TAMs
Macrophages are the most prominent population of noncancer cells in tumours, and are known as tumourassociated macrophages (TAMs) (Liu and Cao, 2015) . In the tumour stroma, the emergence of TAMs often indicates a poor prognosis in numerous neoplasms related to angiogenesis, which is a vital and complex process that is of great concern in oncogenesis (Liss et al., 2002) . Infiltration of TAMs often appears in histological sections of head and neck squamous cell carcinoma (HNSCC), and TAMs are conducive to HNSCC angiogenesis and increase the development of the angiogenic phenotype (Polverini and Leibovich, 1987; Liss et al., 2001) . Thus, strategies that block the recruitment of macrophages into the tumour microenvironment are helpful in antiangiogenic therapies for HNSCC. Furthermore, preclinical studies have shown that blocking macrophage recruitment into tumours can increase the response to cytotoxic therapy (DeNardo et al., 2011; Shiao et al., 2015) . Liss et al. (2002) demonstrated that RA suppresses the recruitment and activation of monocytes involved in tumour angiogenesis. The capacity of TAMs to facilitate the angiogenic process was found to be altered by RA, which directly blocks their migration towards chemotactic factors such as monocyte chemoattractant protein-1 and TGF-β1, that normally show enhanced expression in HNSCC (Liss et al., 2002) . Additionally, RA-treated tumour cells show a reduced secretion of TGF-β1, hence, the generation of VEGF and IL-8 that were induced by TAMs was remarkably decreased in RA-treated tumour cells (Liss et al., 2002) . These studies indicate that treatment of tumour cells with RA also inhibits the activation of TAMs. These effects on TAMs in RA-treated tumour cells can lead to slower growth and a reduction in tumour aggression on account of a decrease in vascularity. Moreover, researchers have found that retinoids played a vital role in the formation of abdominal macrophages. RA from local tissue can modulate specific gene expression of multiple abdominal macrophages by the transcription factor GATA-6 to control the recruitment of macrophages into enterocoelia, which may affect the initiation and development of gastroenteric tumours (Okabe and Medzhitov, 2014) .
Retinoids suppress the M2 polarization of macrophages
Based on diverse responses to distinct stimulation in the micro-environment, macrophages can be classified into two extreme subsets, namely, classically activated (M1) and alternatively activated (M2) macrophages, which take on quite different functions (Cassetta et al., 2011) . Current studies show that in contrast to the antitumour effect of M1 macrophages, M2 macrophages are deemed to promote tumour progression. In most malignant tumours, macrophages are usually in the form of M2 polarization. Although the molecular mechanisms of macrophage polarization have not been fully elucidated due to the intricate network, the macrophage is a promising target for cancer therapy.
Fenretinide (4-HPR), a synthetic derivative of ATRA, has been shown to be an effective cancer treatment with minor side effects (Ulukaya and Wood, 1999) . We and other research groups have discovered, from different angles, that 4-HPR exhibits an anti-tumour effect (Torrisi et al., 2000; Johansson et al., 2008; Cao et al., 2009 Cao et al., , 2014 Cuperus et al., 2010; Dong et al., 2017) . Furthermore, 4-HPR has been shown, in clinical trials, to have a bright future as both a chemopreventive agent in breast, bladder and oral mucosal cancers and a chemotherapeutic agent in paediatric and adult cancers. We have recently found that 4-HPR can inhibit M2 macrophage polarization by suppressing the phosphorylation of signal transducers and activators of transcription 6 (STAT6) in colon cancer (Dong et al., 2017) . 4-HPR efficiently inhibits the M2 polarization of macrophages induced by IL-4/ IL-13 in both RAW264.7 cells and bone marrow-derived macrophages (BMDMs) from mice, with decreased expression of CD206, the surface marker of M2 macrophages (Dong et al., 2017) . Instead of the classical ROS pathway, our findings suggest that the STAT6 signalling pathway is involved in 4-HPRmediated inhibition of M2 polarization (Dong et al., 2017) . In APC min/+ transgenic mice, 4-HPR significantly reduced the number of intestinal tumours compared to the control group without affecting body weight (Dong et al., 2017) . In addition, in a recent study we also found that M2 macrophages can promote the pulmonary metastasis of osteosarcoma with enhanced expression of CD209 + , a marker protein of M2 macrophages, while a negative result was obtained for CD86 + , a marker protein of M1 macrophages in lung metastasis loci (Zhou et al., 2017) . Interestingly, ATRA can selectively inhibit the M2 polarization of macrophages and suppress their migration (Zhou et al., 2017) . The potential underlying mechanism of this inhibitory effect of ATRA on the M2 polarization of macrophages is the inhibition of MMPs, especially MMP12 (Zhou et al., 2017) . These findings highlight the possibility that the inhibition of M2 polarization of macrophages might be one of the general mechanisms that underlie the chemopreventive effect of retinoids.
Retinoids exhibit remarkable effects on T cells
T cells, which are derived from bone marrow pluripotent stem cells, are the largest and most complicated group of lymphocytes. Based on their different functions and surface markers, T cells are categorized into several types. In addition to autoimmune diseases, viral infections and allergic reactions, T cells have strong effects on the initiation and development of malignant tumours. For instance, Tc cells have been shown to inhibit tumour cells that express self-tumour antigens in murine tumour models and in pancreatic cancer patients (Ryschich et al., 2005) . Treg cells can maintain immune tolerance to prevent excessive activity of effector T cells (Te cells) and overloading of the immune response (Carratu et al., 2012) . Memory T cells (Tm cells) have been observed to be good immunological indexes for the stage of gastric cancer. The immunosuppression and immune response to the tumour-associated antigen can be reflected by the percentage of Tm subsets . Given that the immune therapies that have been used in the clinic to date are based on the functions of T cells, studies on the modulatory effects of retinoids on T cells are attracting increasing attention in this field.
Retinoids shape Th1/Th2 responses and suppress the development of the Th17 cell response
Th cells, which mainly include Th1, Th2, Th9 and Th17 cells, assist humoural and cellular immunity. Different types of Th cells exhibit distinct functions, and their differentiation is one of the main processes that influence the specific immune response (Alizadeh et al., 2014) . The balance of cell populations between Th1 and Th2 cells is of great significance for the generation of adaptive immune responses. Th1 cells are protective against intracellular pathogen infections, while Th2 cells are mostly responsible for antibody production and protection against extracellular parasites in humoural immunity. In a clinical study of colon cancer patients, a high expression of the Th1 cluster implied prolonged disease-free survival, while expression of the Th2 cluster was not predictive of prognosis. In contrast, patients with a high expression of the Th17 cluster exhibited a poor prognosis (Tosolini et al., 2011) . Studies have shown that vitamin A deficiency renders the immune response to tend towards the Th1 direction. Nevertheless, the response may tend towards the Th2 direction when plenty of vitamins are ingested (Alizadeh et al., 2014) . It has been reported that retinoid X receptor-α (RXR-α) signalling, which is activated by 9-cisRA, usually inhibits the differentiation of naive CD4 + T cells into Th1 cells (Spilianakis et al., 2005) . Iwata et al. (2003) found that, in addition to 9-cisRA, ATRA suppresses the development of Th1 cells but enhances the level of Th2 cells level. They also demonstrated that RA has direct effects on Th cells to suppress the development of Th1 and promote that of Th2 via RARs (Iwata et al., 2003) . However, another study conducted by Stephensen et al. (2004) indicated that vitamin A induces the Th1 response instead of the Th2 response. In addition to shaping the Th1/Th2 responses, RA inhibits the development of Th17 cell responses in vivo and reduces disease severity in experimental autoimmune encephalitis, an autoimmune disease that is mediated by Th17 cells (Xiao et al., 2008) . Mucida et al. studied the impact that RA had on the differentiation of Th17 cells; they observed that RA can function as a key modulator of TGF-β, drive regular immune deviation, suppress the differentiation induced by IL-17 and further restrain Th17 cell differentiation (Mucida et al., 2009) . Moreover, retinoids have been found to be important regulators in the Th1/Th17 versus Th2 balance and to suppress the adverse development of the Th17 cell response (Carratu et al., 2012) .
Retinoids and TGF-β have a synergistic effect on the generation and function of Treg cells

Treg cells are negative regulators and can inhibit the functions of other immune cells, including natural regulatory T cells and adaptive T cells (aTreg cells). Treg cells play a critical role in maintaining immune tolerance and suppressing the excessive activity of Te cells. The expression of Foxp3
+ , the forkhead/winged helix transcription factor family member, is induced by TGF-β to influence the level of Treg cells when IL-2 is present (Carratu et al., 2012) . It is well known that ATRA promotes the generation and development of TGF-β-induced CD4 + Foxp3 + aTreg cells and enables the development of aTreg cells in the presence of overt inflammation; thus, ATRA plays a vital role in the immune system during oncotherapy (Benson et al., 2007; Lu et al., 2011) . In addition to increasing the frequency and durability of these aTreg cells, ATRA also promotes Foxp3 expression (Benson et al., 2007) . Another study suggests that RA significantly up-regulates Foxp3 + together with TGF-β in the presence of IL-2. Ultimately, RA enhances the expansion of Treg cells (Mucida et al., 2009) . RA-induced Foxp3 + Treg cells function as a modulator in maintaining a stable level of tolerance to antigens, accordingly preventing excessive immune responses (Strober, 2008) . In addition to its effect on TGF-β-induced Treg expansion in peripheral tissues, RA enhances the generation of Treg cells, which are induced by antigenpresenting DCs in gut-associated lymphoid tissue. In addition, the expression of gut-homing receptors in Treg cells is up-regulated (Fleissner et al., 2011 Du et al. (2005) reported that the functional activity of Treg cells is reduced when RXR signalling is blocked, which suggests that the RXR pathway has a role in the generation of Treg cells. (Allie et al., 2013) . When activated Tcm are re-stimulated, they can produce large numbers of Tem cells, which home to peripheral sites and are the first to respond after re-exposure to antigens, and subsequently, the immune response is activated (Sallusto et al., 2004) . In addition, Tm cells are also classified into CD4 + and CD8 + Tm cells; CD8 + Tm cells exhibit cytotoxicity, present more versatile functions and manifest a much wider variety of differentiation patterns than CD4 + Tm cells (Klebanoff et al., 2006) .
RA signalling is of great importance in the differentiation of Tm cells
CD8
+ Tm cells form well-differentiated short-lived effector cell (SLEC) and memory-precursor effector cell (MPEC) populations upon activation. When CD8 + Tm cells migrate to the tumour tissue, they can differentiate into Te cells and suppress the growth of tumours (Hwang et al., 2007) . Allie et al. (2013) showed that RA signalling is of great importance for optimal effects by CD8 + T cells. ATRA stimulates CD8 + T cells to differentiate into their highly differentiated phenotype, SLECs; and their findings suggested that the MPEC phenotype was due to developmental defects instead of the absence of RA signalling (Allie et al., 2013) . Additionally, an enhanced central memory phenotype was observed with increased CD127 and IL-2 in the absence of RA signalling, which was consistent with the functional test (Allie et al., 2013) . Another hypothesis is that the loss of RA may cause the effector portion of the MPEC phenotype to stop functioning, which results in an increase in the central memory population. Considering that the generation of functional Tm cells is impaired in tumours, the role that RA signalling plays in the differentiation of Tm cells should be investigated further as a promising therapeutic target.
Retinoids are responsible for the differentiation, maturation and function of DCs
DCs are professional antigen-presenting cells that are derived from bone marrow, and they function in the uptake, processing and presenting of antigens to T cells. By generating cytotoxic T-lymphocytes to induce primary immune responses, DCs have a crucial impact on all types of immunotherapies (Reid, 2001) . RA displays an inhibitory effect on the allostimulatory capacity of DCs in animal models, which is dose-dependent (Bedford and Knight, 1989) . In cancer patients, the proportion of immature DCs (imDCs) is reduced while the ratio of myeloid/lymphoid DCs is increased by ATRA treatment, which leads to improved DC function and response in an antigen-specific manner (Mirza et al., 2006) . However, Tao et al. (2006) found that the differentiation and maturation of DCs were inhibited by ATRA treatment with a decrease in IL-12 and IFN-γ secretion and an increase in IL-10 and IL-4 generation, which suggests that DCs treated with ATRA drive T cells towards the Th2 response. Jin et al. (2010) observed that ATRA could result in cell death concomitantly with the production of DCs, particularly in the case of cell differentiation. Research has shown that RA signalling transduced through RAR/RXR can induce the apoptosis of imDCs in a caspase-dependent manner (Geissmann et al., 2003) . The functional capacity of antigen uptake by imDCs is also decreased when cultured in the presence of ATRA, the same as allogeneic T cell stimulatory capacity (Jin et al., 2010) . Additionally, ATRA treatment did not lead to significant toxicity.
Therefore, it could be tested as a therapeutic in combination with cancer vaccines (Mirza et al., 2006) . In addition to ATRA, it has been found that RA signalling controls the generation and development of conventional DCs (cDCs) in the intestine, and affects the expression of their transcription factors, such as Notch2, Prdm1 and Irf4 (Zeng et al., 2016) .
Conclusion and prospect
Retinoids have been considered to be promising chemotherapeutic and chemopreventive agents due to their attractive anti-tumour effects. For example, low doses of retinol and retinyl acetate are used to inhibit several skin tumours; 9-cisRA has the potential to prevent mammary and prostate cancer; ATRA can trigger the apoptosis of human liver cancer cells (Bushue and Wan, 2010) ; 4-HPR suppresses the development of colon cancer; and 13-cisRA is effective in preventing head and neck cancer (Bushue and Wan, 2010) . In addition, combination therapies with retinoids and trastuzumab may benefit breast cancer patients because of their amazing ability to inhibit cell growth and induce apoptosis of cancer cells (Koay et al., 2010) . However, the use of retinoids is partly limited by their side effects such as teratogenesis, a drying out of mucous membranes, a rise in blood lipid levels and liver damage. In recent years, tumour immunotherapy has received greater attention because of its remarkable curative effect in the treatment of cancer (Fleissner et al., 2011; Kochenderfer et al., 2012; Hamid et al., 2013; Anguille et al., 2014; Schadendorf et al., 2015; Zhu et al., 2016) . Many years ago, people were aware that a deficiency in vitamin A could result in inflammation, but the underlying molecular mechanism was not completely understood. Recently, scientists have gradually uncovered the mechanism through which retinoids regulate innate and adaptive immunity. Diverse and important functions that are exhibited by retinoids, including the regulation and control of cell proliferation and the differentiation and activation of tumour suppressor genes, are related to its efficacy at regulating immune cells, which has received increasing attention (Table 2, Figure 3) . Research indicates that retinoids essentially affect the differentiation, recruitment and polarization of TAMs, which influence the initiation and development of multiple cancers. Their impact on diverse T cells, including the balance between Th1 and Th2 cells, the generation and function of Treg and Tem cells and the ratio of CD4/CD8 cells, is responsible for the change in the tumour immune system and, thus, plays a vital role in oncotherapy (Spilianakis et al., 2005; Benson et al., 2007; Allie et al., 2013) . Additionally, ATRA treatment inhibits the differentiation and maturation of DCs, and also improves DC function and the antigen-specific immune response (Jin et al., 2010) .
Although retinoids have been proved to be promising anti-tumour drugs, the mechanisms underlying their antineoplastic effect have not been fully clarified. It is well known that the induction of apoptosis participates in the antitumour process. However, the mechanisms through which retinoids induce apoptosis remain unknown. The extensive impact that retinoids have on immune cells partially explains their remarkable anti-neoplastic effect from another perspective. The regulatory effects of retinoids on immune cells make up vast and intricate networks, which contain numerous surprising scientific facts and has profound effects on the progress of antineoplastic therapy. Research ideas in this field have been expanded by taking into consideration the effects that retinoids exert on immune cells (Alizadeh et al., 2014) . Insight into the role of retinoids in regulating immune cells provides a new approach towards studying anti-tumour strategies and offers novel ideas to determine new targets. (Chen and Ross, 2004) 1 μM 7 days Recruitment and activation of TAMs (Liss et al., 2001) 1 μM 48 h M2 polarization of macrophages (Zhou et al., 2017) 10 nM 4 days Shape Th1/Th2 responses (Iwata et al., 2003) 10 nM 4 days SuppressTh17 cells differentiation (Xiao et al., 2008) 10 nM 5 days Generation and function of Treg cells (Benson et al., 2007) 1 nM 6 days Differentiation and maturation of DCs (Tao et al., 2006) 1 nM 9 days Function of DCs (Tao et al., 2006) 4-HPR DMSO 5 μM 3 days M2 polarization of macrophages (Dong et al., 2017) 9-cisRA DMSO 10 nM 4 days Shape Th1/Th2 responses (Iwata et al., 2003) 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b) .
Figure 3
The role of retinoids in regulating immune cells. Retinoids promote the differentiation of macrophages, inhibit the recruitment and activation of TAMs and depress M2 polarization of macrophages. With regard to T lymphocytes, retinoids shape Th1/Th2 responses and suppress the development of Th17 cell response; retinoids and TGF-β act synergistically to promote the generation and function of Treg cells. Also, RA signalling has an important role in the differentiation of Tm cells. Retinoids are responsible for the differentiation, maturation and function of DCs.
